CYP2C76 deficiency is embryonic lethal in cynomolgus macaques: The potential role of CYP2C76 in early embryogenesis

被引:0
作者
Koyama, Shuzo [1 ,2 ]
Fukuda, Koji [1 ,2 ]
Watanabe, Sho [1 ,2 ]
Matsushita, Akinori [1 ,3 ]
Tsuchiya, Hideaki [4 ]
Fujinami, Nahoko [5 ]
Kohara, Sakae [3 ]
Murayama, Norie [6 ]
Nagano, Masashi [7 ]
Yamazaki, Hiroshi [6 ]
Fukuzaki, Koichiro [1 ,2 ]
Uno, Yasuhiro [3 ]
Hosoi, Yoshihiko [5 ]
机构
[1] Drug Safety Res Ctr DSR, Shin Nippon Biomed Labs SNBL Ltd, Kagoshima, Japan
[2] SNBL USA Ltd, Everett, WA USA
[3] Pharmacokinet & Bioanal Ctr, Shin Nippon Biomed Labs Ltd, Kainan, Japan
[4] Shiga Univ Med Sci, Res Ctr Anim Life Sci, Otsu, Shiga, Japan
[5] Kinki Univ, Grad Sch Biol Oriented Sci & Technol, Kinokawa, Japan
[6] Showa Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Machida, Tokyo, Japan
[7] Hokkaido Univ, Grad Sch Vet Med, Dept Vet Clin Sci, Lab Theriogenol, Sapporo, Hokkaido, Japan
关键词
Cytochrome P450; Embryogenesis; Progesterone; Null allele; Cynomolgus macaque; LIVER-MICROSOMES; CYTOCHROME-P450; MONKEY; POLYMORPHISMS; TESTOSTERONE; METABOLISM; VARIANTS; MOUSE;
D O I
10.1016/j.dmpk.2016.10.411
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cynomolgus macaques are an important primate species for drug metabolism studies; however cynomolgus CYP2C76, an important drug-metabolizing enzyme, accounts for drug metabolism differences to humans, so that CYP2C76-null animals might show drug-metabolizing properties more similar to humans. In this study, attempts were made to produce CYP2C76-null animals by assisted reproduction technology. Oocytes and sperm collected from the heterozygotes for the null allele (c. 449TG > A) were subjected to intracytoplasmic sperm injection, and the embryos produced were cultured in vitro through the blastocyst stage. Preimplantation genetic diagnosis using a biopsied portion of the blastocyst revealed that none of the 32 blastocysts analyzed were homozygotes. In contrast, 2 of the 20 embryos analyzed were homozygotes at the 8-cell stage, indicating that CYP2C76-null embryos most likely stop developing between the 8-cell and blastocyst stage. By polymerase chain reaction, expression of CYP2C76 mRNAwas detected in oocytes and blastocysts, but not in 2-, 4-, 8-, or 16/32-cell stage embryos. Metabolic assays showed that CYP2C76 metabolized progesterone. These results indicated that CYP2C76 null was likely embryonic lethal, suggesting its potential role during early embryogenesis in cynomolgus macaques. (C) 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:112 / 115
页数:4
相关论文
共 50 条
  • [31] Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment
    Jose Cerezo-Manchado, Juan
    Roldan, Vanessa
    Rosafalco, Mario
    Isabel Anton, Ana
    Belen Arroyo, Ana
    Garcia-Barbera, Nuria
    Belen Martinez, Ana
    Padilla, Jose
    Corral, Javier
    Vicente, Vicente
    Gonzalez-Conejero, Rocio
    PHARMACOGENOMICS, 2014, 15 (07) : 987 - 996
  • [32] Analysis of the Potential Association of Drug-metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations with Type 2 Diabetes: A Case-control Study
    Elfaki, Imadeldin
    Mir, Rashid
    Abu-Duhier, Faisel M.
    Jha, Chandan K.
    Al-Alawy, Adel, I
    Babakr, Abdullatif Taha
    Habib, Salem Abd El-Hadi
    CURRENT DRUG METABOLISM, 2020, 21 (14) : 1152 - 1160
  • [33] Pharmacogenetics in Potential Herb-Drug Interactions: Effects of Ginseng on CYP3A4 and CYP2C9 Allelic Variants
    Luu, Alice
    Foster, Brian C.
    McIntyre, Kristina L.
    Tam, Teresa W.
    Arnason, John T.
    BIOLOGICAL ACTIVITY OF PHYTOCHEMICALS, 2011, 41 : 59 - +
  • [34] CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy
    Lin, Jiayao
    Zhang, Yu
    Zhou, Houguang
    Wang, Xinqing
    Wang, Wenwen
    CLINICAL LABORATORY, 2015, 61 (09) : 1317 - 1324
  • [35] Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage
    Kawamura, Taisuke
    Ichikawa, Mako
    Hatogai, Jo
    Koyama, Yuya
    Tachibana, Misa
    Kuwahara, Misaki
    Negishi, Keita
    Matsumoto, Miyu
    Miyazaki, Masafumi
    Ochiai, Wataru
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2022, 43 (04) : 130 - 139
  • [36] The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro
    Pei-Pei Pan
    Qing-Hua Weng
    Chen-Jian Zhou
    Yan-Li Wei
    Li Wang
    Da-Peng Dai
    Jian-Ping Cai
    Guo-Xin Hu
    European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 79 - 86
  • [37] Role of paraoxonase-1 in CYP2C19 loss-of-function carriers
    Daali, Y.
    Reny, J. L.
    Fontana, P.
    THROMBOSIS RESEARCH, 2014, 133 (03) : 519 - 519
  • [38] Gene polymorphism of CYP2C19*2, *3 and CYP3A4*1B and early stent thrombosis: case reports and literature review
    Kulmyrzaeva, Nazgul
    Tatarunas, Vacis
    Skipskis, Vilius
    Smagulova, Gaziza
    Seitmaganbetova, Nazgul
    Veikutiene, Audrone
    Lesauskaite, Vaiva
    PERSONALIZED MEDICINE, 2016, 13 (05) : 423 - 428
  • [39] New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4
    Mwinyi, Jessica
    Nekvindova, Jana
    Cavaco, Isa
    Hofmann, Yvonne
    Pedersen, Rasmus Steen
    Landman, Ellie
    Mkrtchian, Souren
    Ingelman-Sundberg, Magnus
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) : 415 - 421
  • [40] Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment
    Habtemikael, Lidia
    Russom, Mulugeta
    Bahta, Iyassu
    Mihreteab, Selam
    Berhane, Araia
    Martensson, Andreas
    Gil, Jose Pedro
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 571 - 575